First Hawaiian Bank Biocryst Pharmaceuticals Inc Transaction History

First Hawaiian Bank

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$7.89 - $17.88 $408,189 - $925,021	-51,735 Closed	0 $0
Q1 2022 Apr 06, 2022	BUY	$11.56 - $19.76 $242,413 - $414,367	20,970 Added 68.16%	51,735 $841,000
Q3 2021 Oct 12, 2021	SELL	$14.21 - $17.65 $152,686 - $189,649	-10,745 Reduced 25.89%	30,765 $442,000
Q2 2021 Jul 08, 2021	SELL	$9.5 - $17.24 $29,545 - $53,616	-3,110 Reduced 6.97%	41,510 $656,000
Q1 2021 Apr 09, 2021	SELL	$7.37 - $13.61 $130,154 - $240,352	-17,660 Reduced 28.36%	44,620 $454,000
Q4 2020 Jan 12, 2021	SELL	$3.37 - $8.61 $9,469 - $24,194	-2,810 Reduced 4.32%	62,280 $464,000
Q3 2020 Oct 06, 2020	BUY	$3.43 - $5.53 $223,258 - $359,947	65,090 New	65,090 $224,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

Stay updated on First Hawaiian Bank with notifications on news.